A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Conditions

• Lipoprotein(a)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• MK-7262 — DRUG
  Oral Coated Tablet
• Enlicitide — DRUG
  Oral Coated Tablet
• Placebo for MK-7262 — DRUG
  Oral Coated Tablet
• Placebo for enlicitide — DRUG
  Oral Coated Tablet

Study Details

Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C). The goals of this trial are to evaluate: * if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood * if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood * the safety and tolerability of taking MK-7262 and enlicitide alone and together

Key Dates

First listed

May 29, 2026

Start date

Jun 30, 2026

Status verified

Jul 2026

Primary completion

Oct 12, 2027

Completion

Oct 12, 2027

Study Design

Enrollment

750 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: Placebo
  Participants will receive MK-7262 placebo + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment.
• Active Comparator: enlicitide monotherapy
  Participants will receive enlicitide + MK-7262 placebo orally once daily (QD) for up to approximately 12 weeks of treatment.
• Experimental: MK-7262 monotherapy
  Participants will receive MK-7262 + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment.
• Experimental: MK-7262 + enlicitide
  Participants will receive MK-7262 + enlicitide orally once daily (QD) for up to approximately 12 weeks of treatment.

Primary Outcome Measure

Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8 [ Time Frame: Baseline and Week 8 ]

Central Contacts

• Toll Free Number
  1-888-577-8839
  [email protected]

Locations (8)

Find similar trials in Mobile, AL

Related Studies

• A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
  PHASE3 · Recruiting · Eli Lilly and Company · La Jolla, California